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Lysophosphatidic acid modulates 
ovarian cancer multicellular 
aggregate assembly and metastatic 
dissemination
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Jing Yang2, Oleg Kim2,4 & M. Sharon Stack2,3*
epithelial ovarian cancer (eoc) metastasis occurs by exfoliation of cells and multicellular aggregates 
(MCAs) from the tumor into the peritoneal cavity, adhesion to and retraction of peritoneal mesothelial 
cells and subsequent anchoring. elevated levels of lysophosphatidic acid (LpA) have been linked 
to aberrant cell proliferation, oncogenesis, and metastasis. LPA disrupts junctional integrity and 
epithelial cohesion in vitro however, the fate of free-floating cells/MCAs and the response of host 
peritoneal tissues to LPA remain unclear. EOC MCAs displayed significant LPA-induced changes in 
surface ultrastructure with the loss of cell surface protrusions and poor aggregation, resulting in 
increased dissemination of small clusters compared to untreated control McAs. LpA also diminished 
the adhesive capacity of eoc single cells and McAs to murine peritoneal explants and impaired McA 
survival and mesothelial clearance competence. Peritoneal tissues from healthy mice injected with 
LpA exhibited enhanced mesothelial surface microvilli. Ultrastructural alterations were associated 
with restricted peritoneal susceptibility to metastatic colonization by single cells as well as epithelial-
type MCAs. The functional consequence is an LPA-induced dissemination of small mesenchymal-type 
clusters, promoting a miliary mode of peritoneal seeding that complicates surgical removal and is 
associated with worse prognosis.
With > 14,000 fatal cases in the United States and ~ 152,000 deaths worldwide per annum, ovarian cancer invari-
ably remains the most lethal malignancy of the female reproductive  system1–3. Predominantly (~ 90% of cases) 
affected by the most aggressive type of ovarian cancer—epithelial ovarian carcinoma (EOC), women usually 
present with widespread intraabdominal metastases at primary diagnosis, resulting in poor disease prognosis. 
Importantly, while surgical tumor debulking and standard platinum/taxane-based chemotherapy in such patients 
are initially efficacious, most women ultimately develop disease recurrence in the form of multi-drug resistant 
intraperitoneal metastasis, resulting in a 5-year relative survival rate of only 30%4, 5.
In a multi-step EOC intraperitoneal (transcoelomic) metastasis process, ovarian cancer cells escape the 
primary tumor individually or in cell:cell adherent cohorts by direct desquamation into the abdominal cavity. 
Buildup of malignant ascitic fluid further expedites intraperitoneal transport as anoikis-resistant single cells and 
multicellular aggregates (MCAs, or spheroids). The latter ultimately colonize and retract the mesothelial mon-
olayer of peritoneally-lined abdominal organs, anchor in the submesothelial extracellular matrix (ECM) and pro-
liferate to form metastatic  nodules6–8. Formation of metastatic cells into MCAs is confirmed by their abundance in 
EOC patients’ effusions and in ascitic fluids collected from mice bearing intraperitoneal xenografts (our unpub-
lished observations) and is considered one of the crucial steps ensuring successful metastatic  dissemination9–11. 
Studies indicate that MCAs are more anoikis-, radio- and chemoresistant in comparison with single  cells8, 12–15. 
MCAs also exhibit a higher propensity for immune  evasion16, 17 and cancer stem cell  potential18–20, as well as 
enhanced capacity for mesothelial clearance and ECM invasion at the secondary metastatic  site21, 22. However, 
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current understanding of the factors that control the cell–cell aggregation process into a multicellular meta-
static unit and regulation of its subsequent fate remains largely elusive. Multiple molecules have been reported 
to impact ovarian cancer MCA generation and pro-metastatic behavior, including  integrins23,  cadherins21, 24, 
 fibronectin25, matrix  metalloproteinases26,  CD4427,  CDC25A28, angiotensin  II29, nectin-430 and others. Most 
importantly, modulation of the expression or activity of these proteins altered MCA clustering and impacted 
their pro-metastatic properties. Therefore, elucidating molecular mechanisms influencing MCA generation and 
dynamics may identify strategies to impair MCA formation and survival and thereby favorably reduce metastatic 
seeding.
During EOC transcoelomic dissemination, ovarian cancer cells and MCAs are subjected to a variety of exter-
nal signals prevalent in the ascitic microenvironment. Lysophosphatidic acid (LPA) is a ubiquitous bioactive 
growth factor-like phospholipid that acts through a subfamily of G-protein coupled cell surface LPA-specific 
receptors (LPARs), evoking proliferative, adhesive/migrative/invasive and pro-survival responses in  cells31–34. 
LPA is prevalent in the malignant ascites of EOC patients (1–80 μM) as compared to effusions from healthy 
individuals and women with benign ovarian neoplasms or non-malignant ascitic  transudate31, 35–37. As opposed 
to normal ovarian epithelial cells which do not produce LPA at levels significant enough to stimulate aberrant 
receptor  activation38, in EOC constitutive production of LPA by both ovarian cancer cells and mesothelial cells 
of the  peritoneum38, 39 increases EOC cell adhesive, migratory and invasive properties, colony formation in vitro 
as well as tumorigenesis/metastasis in vivo39–41.
Multiple studies report a variety of mechanisms through which LPA triggers epithelial-to-mesenchymal 
transition (EMT)7. For example, it has been postulated that autotaxin, an enzyme responsible for production 
of LPA from lysophosphatidylcholine, can maintain an ovarian cancer stem cell population through an auto-
crine  mechanism42. However, the role of LPA in modulating the intraperitoneal dynamics of MCAs remains 
understudied. Our group has previously reported time- and dose-dependent LPA-mediated disruption of EOC 
cell–cell connections through MMP-9-catalyzed E-cadherin extracellular domain cleavage resulting in loss of 
cell junctional integrity and epithelial cohesion, which could be restored by LPAR  blocking43. Subsequently, we 
have demonstrated that LPA-treated cells and MCAs release a large cohort of  proteins7, 44. In the current study 
we seek to comprehensively characterize the contribution of LPA to regulation of EOC MCA dynamics and 
peritoneal colonization through evaluating early adhesive events in peritoneal seeding.
Results
LpA decreases eoc cell aggregation capacity. We previously demonstrated that MCAs generated 
from epithelial- and mesenchymal-type ovarian cancer cells possess dramatically different phenotypes, ranging 
from loosely adhesive clusters (formed by purely epithelial-type E-cadherin expressing EOC cells) to highly 
cohesive solid spheroids (formed by purely mesenchymal-type N-cadherin-expressing EOC cells)24. To address 
the potential effect of LPA on MCA formation, in the current study we utilized an epithelial-type OvCa429 cell 
line, a mesenchymal-type DOV13 cell line and the highly mesenchymal SKOV3ip cell line that was selected for 
in vivo aggressive behavior. When incubated in hanging drops, OvCa429, DOV13 and SKOV3ip single cells 
readily assembled into a single MCA per drop. However, in the presence of LPA (80 μM), all three cell lines 
exhibited decreased aggregation capacity and formed multiple smaller clusters (Fig. 1A, Supplemental Fig. 1).
As our group has previously reported disruption of cell–cell junctions in cell monolayers by LPA, promoting 
their  dissemination43, here we sought to further understand whether the observed alterations in MCA assembly 
rely on the continued presence of LPA in suspension. Four different LPA treatment regimens were implemented 
(Fig. 1B): (a) EOC cells grown as two-dimensional (2D) monolayers and subsequently seeded to grow three-
dimensionally (3D) in hanging drops were left untreated (designated ‘2D − 3D−’); (b) EOC cells were grown in 
monolayers without LPA and further treated with 80 μM LPA in hanging drops (‘2D − 3D+’); (c) EOC cells were 
grown in monolayers with 80 μM LPA and subsequently incubated without LPA in hanging drops (‘2D + 3D−); 
(d) EOC cells were treated with 80 μM LPA both in monolayers and hanging drops (‘2D + 3D−’). As observed 
via light microscopy (Fig. 1B), OvCa429 and SKOV3ip EOC cells demonstrated impaired aggregation under 
2D − 3D+ and 2D + 3D+ LPA treatments in comparison with the control 2D − 3D− condition. Interestingly, how-
ever, both OvCa429 and SKOV3ip cells incubated under 2D + 3D− LPA treatment exhibited avid MCA formation 
similarly to that of fully untreated 2D − 3D− control, suggesting that the effects of pre-treatment are reversible.
LPA alters EOC cell/MCA surface ultrastructure. To further decipher the effect of LPA on ovarian can-
cer MCA morphology, MCAs generated using the four LPA treatment regimens described above were visualized 
via SEM (Fig. 2). Remarkable differences in surface ultrastructure were observed correlating with LPA-treatment 
protocol. While untreated 2D − 3D− aggregates displayed high level of clustering, cell surface area and complex-
ity (uniform microvilli coverage of OvCa429 MCAs and pronounced invasive filopodia coverage of metastati-
cally aggressive SKOV3ip MCAs), poorly assembled 2D − 3D+ and 2D + 3D+ LPA-treated aggregates exhibited 
smooth cell surfaces with complete loss of protrusions in both cell types (Fig. 2). Inclusions in the samples were 
also observed, likely representing material released from cell surface in the presence of LPA (Fig. 2, arrows). To 
evaluate the nature of these inclusions, a comprehensive chemical analysis by multiplex coherent anti-Stokes 
Raman scattering imaging combined with mass spectrometry was performed. The results confirmed that the 
proteinaceous nature and composition of these structures were matched to the surface of the LPA-exposed cells/
MCAs44. In support of the reversible nature of the ultrastructural changes, scanning electron micrographs of 
2D + 3D− LPA-treated OvCa429 and SKOV3ip MCAs depicted surface morphology patterns identical to those 
of corresponding fully untreated MCAs (Fig. 2).
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LpA reduces eoc cell adhesion to peritoneal tissues. As an early event in metastatic dissemination, 
EOC cells first encounter a monolayer of mesothelial cells that overlie a thin basement membrane and serve as 
an active barrier between tumor cells and the underlying submesothelial collagen-rich 3D ECM (Fig. 3A). The 
integrity of this mesothelial cell monolayer is key to regulation of metastatic dissemination and research indi-
cates that cancer cells adhere more readily to areas of the peritoneum exhibiting cleared  mesothelium45, 46. By 
examining ex vivo peritoneal tissue explants under SEM, we commonly observed that individual SKOV3ip cells 
Figure 1.  Exposure to LPA impairs ovarian cancer MCA assembly. (A) Fluorescently tagged (RFP or GFP) 
human EOC cells were seeded in 20 µl hanging drops at a 100,000 cell/ml concentration with or without 80 µM 
LPA (Cayman Chemical, Ann Arbor, MI) and incubated for 48–72 h. Imaging was then performed using 
AMG EVOS fluorescent microscope, scale bar = 400 µm. (B) Schematic and microscopic representation of 
MCAs generated under different LPA treatment conditions: EOC cells were grown in TC dishes until 60–70% 
confluence, incubated with or without 80 µM LPA for 24 h, harvested, seeded in 20 µl hanging drops at a 
100,000 cell/ml concentration with or without 80 µM LPA. 4 different LPA treatment regimens were used: (a) 
cells were not treated with LPA in TC dishes and hanging drops (2D − 3D−); (b) cells were treated in hanging 
drops only (2D − 3D+); (c) cells were treated in TC dishes only (2D + 3D−); (d) cells were treated both in TC 
dishes and in hanging drops (2D + 3D+). After 48–72 h MCAs were imaged under light microscope (× 10).
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Figure 2.  LPA reversibly alters EOC cell/MCA surface morphology. MCAs were generated from OvCa429 
and SKOV3ip cells, as indicated, via the hanging drop method using LPA treatment conditions outlined in 
Fig. 1B; processed for SEM as detailed in “Methods”; and examined using FEI-Magellan 400 field emission SEM. 
Representative images were taken at × 1,000, × 7,000, and × 15,000 magnifications (scale bars as indicated), 
arrows depict sample inclusions released from cell surface.
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rapidly adhered to and spread upon peritoneal zones with exposed collagen (Fig. 3B, left), in contrast to cancer 
cells attaching directly to mesothelium, which did not exhibit spreading (Fig. 3B, right). To delineate the poten-
tial impact of LPA on the ability of EOC cells and MCAs to colonize mesothelium, adhesion to intact peritoneal 
Figure 3.  LPA attenuates EOC cell adhesion to murine peritoneal tissues. (A) Pseudo-colorized SEM 
micrograph of a C57BI/6 mouse peritoneal tissue (dissected, processed for SEM and imaged as detailed 
in “Methods”) visualizes microvilli-covered mesothelial cells (MC, yellow) which form a monolayer atop 
underlying 3D collagen-rich submesothelial extracellular matrix (arrow). The integrity of the MC monolayer in 
the current micrograph was surgically compromised during the dissection procedure and allows visualization 
of the underlying ECM collagen fibers (arrow). Red blood cells—erythrocytes (red) and echinocytes (purple)—
are also in the field of view. (B) Scanning electron micrographs of ovarian cancer SKOV3ip cells seeded 
atop C57BI/6 mouse peritoneal explants (dissected, cell-seeded, SEM-processed and imaged as detailed in 
“Methods”) display adhesion and dispersal of an individual ovarian cancer (OvCa) cell on top of naked collagen 
(Col) vs. mesothelium (Mes) after 1 h of seeding. (C) Schematic representation of the peritoneal adhesion 
assay: fluorescently labeled OvCa429, DOV13, and SKOV3ip cells, pre-treated or not treated with 80 µM LPA 
(2D+ or 2D−), were seeded on dissected and pre-pinned C57Bl/6 murine peritoneal explants and incubated for 
times indicated; tissues were then examined using EVOS fluorescence microscope or SEM FEI-Magellan 400 as 
detailed in “Methods”; (D) quantitative analysis of images was performed in ImageJ and statistical significance 
(defined as **p < 0.01, ***p < 0.001) was calculated using a two-sided Mann–Whitney U test. The data are 
presented as mean ± SD. Scale bars: as indicated.
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explants was quantitatively  evaluated24 using fluorescently labeled cells or MCAs (Fig. 3C). LPA pre-treatment of 
EOC cell 2D monolayers significantly decreased adhesion of individual cells to peritoneal explants (Fig. 3D–F). 
It is interesting to note that differences between treated and untreated highly aggressive SKOV3ip cells were 
observed at early time point, but by 1 h, all of the cells were fully adherent.
LPA attenuates EOC MCA-to-mesothelium adhesion and mesothelial clearance. As reported 
above (Figs. 1, 2), LPA impedes aggregation of cells into larger MCAs. To access the pro-metastatic behaviors of 
EOC MCAs at the peritoneal site via the peritoneal adhesion assay (described in Fig. 3B), EOC cells were incu-
bated in hanging drops with or without 80 μM LPA (3D+ or 3D−, respectively) for 48 h and then an equal num-
ber of drops were collected for each condition and reseeded onto live murine peritoneal explants. Evaluation of 
attached MCAs using fluorescence microscopy revealed altered adhesion patterns in all cell lines (Fig. 4A,C,E, 
greyscale panels). Overall analysis of the size distribution of adhered MCAs or spheroids demonstrated an LPA-
induced shift towards a miliary pattern of peritoneal seeding (Fig. 4A,C,E, colored panels).
Upon examination of peritoneal explants under SEM, noticeable differences in MCA dispersal and mesothelial 
clearance function were observed. In particular, untreated OvCa429, DOV13 and SKOV3ip MCAs displayed 
lateral dispersal of MCA leading cells, migration underneath mesothelium, disruption and clearance of damaged 
mesothelial layer and exposure of underlying collagen (Fig. 4B,D,F, left panels) within 2 h of seeding. In striking 
contrast, LPA-treated epithelial-type OvCa429 MCAs fully segregated on top of uncompromised mesothelial 
monolayer and underwent full aggregate destruction, as evidenced by disintegration of ovarian cancer cell mem-
brane and loss of intracellular cytoplasmic content (Fig. 4B, right panel). In turn, LPA-treated mesenchymal-type 
DOV13 and far-mesenchymal-type SKOV3ip MCAs exhibited partial segregation and cell death atop mesothe-
lial layer similar to that of OvCa429; nevertheless, some of DOV13 and SKOV3ip cells survived and partially 
retracted the mesothelium, although to a lesser level relative to untreated MCAs (Fig. 4D,F, right panels).
LpA modulates host peritoneal tissue ultrastructure. While a multitude of studies focus on the role 
of LPA in promoting cancer cell oncogenic functions, the impact on host peritoneal tissues remains uninves-
tigated. To address this question, C57BI/6 female mice were injected intraperitoneally daily with LPA or PBS 
for 5 consecutive days or left un-injected. Subsequent SEM examination of peritoneal explants revealed that 
non-injected and PBS-injected mice shared similar peritoneal morphology. In contrast, LPA-injected mice dem-
onstrated significantly enhanced mesothelial surface area and complexity as evidenced by augmented density 
and length (but not thickness) of mesothelial cell surface microvilli (Fig. 5, Supplemental Fig. 2). Of note, one 
time short-term (30 min) intraperitoneal administration of LPA (80 μM) did not cause ultrastructural changes 
in murine peritoneal tissues compared to PBS-injected or non-injected controls (data not shown), suggesting 
that this is not an acute response.
LPA restricts mesothelial susceptibility to EOC single cells and epithelial-type EOC MCAs. To 
further evaluate functional consequences of LPA-induced ultrastructural changes in tumor cell and mesothelial 
tissue ultrastructure, an ex vivo peritoneal adhesion assay was employed, wherein fluorescently labeled EOC 
single cells or MCAs were applied to peritoneal explants obtained from un-treated or LPA-treated (5 days) mice 
and evaluated by fluorescence or scanning electron microscopy (Fig. 6A). Adhesion of single cells to peritoneal 
tissues from LPA pre-treated mice was significantly reduced regardless of the epithelial or mesenchymal pheno-
type of the cell (Fig. 6B). A similar reduction in adhesion of MCAs formed from epithelial phenotype OvCa429 
cells to LPA pre-treated peritoneum was observed (Fig. 6C). Adhesion of MCAs formed from mesenchymal-
type cells was either enhanced (SKOV3ip) or unaffected (DOV13) (Fig. 6C).
Discussion
Despite considerable advances in therapeutic management, EOC has persisted as the deadliest gynecological 
malignancy for decades, thereby clearly illustrating the unmet need for a more fundamental understanding of 
the basic biology that underlies disease progression, aggressive metastatic dissemination and recurrence. LPA 
is abundant in 90% of women with stage I ovarian cancer and 100% of patients with late stages of the  disease47. 
Hence, ovarian cancer cells and MCAs are subjected to LPA signaling at all steps of EOC transcoelomic dissemi-
nation. Multiple studies clearly implicate LPA in ovarian tumorigenesis, EMT regulation, enhanced cancer cell 
adhesion, migration/invasion, proliferation, and regulation of ovarian cancer stem cell  potential7, 39–42, 48. The cur-
rent study reports the unexpected finding that LPA negatively impacts the assembly and implantation of MCAs.
MCAs are now commonly recognized as EOC metastatic units that possess enhanced survival rela-
tive to single cells due to augmented anoikis- and therapeutic resistance and the capacity to sustain immune 
 surveillance8,12–14,16,18. It was recently  demonstrated28 that in comparison with cell monolayers, ovarian multicel-
lular spheroids exhibit chemoresistance through aberrant activation of cell cycle-related pathways, halting cell 
cycle progression and suppressing platinum- or taxane-induced cell death. Moreover, clustering of detached 
cancer cells creates a hypoxic environment and triggers a hypoxia-inducible factor 1-alpha (Hif1α)-mediated 
metabolic switch that restricts reactive oxygen species accumulation. Conversely, disruption of cellular aggregates 
led to reactive oxygen-mediated apoptosis and reduced  metastasis22.
Herein, we demonstrate that LPA promotes loss of EOC cell surface protrusions, impairs the ability to assem-
ble into large MCAs/spheroids, and mitigates adhesion to peritoneal tissues. The functional consequence is an 
LPA-induced dissemination of small clusters, potentially promoting a miliary mode of peritoneal seeding that 
complicates surgical removal and is associated with worse prognosis. Experiments in this study have used con-
centrations of LPA demonstrated to be present in cancerous ascites  fluid31, 35–37. We have previously shown that 
LPA disrupts E-cadherin-mediated junctional integrity in monolayer culture and this effect is blocked by the 
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small molecule inhibitor  Ki1642548. Moreover this was accompanied by gain of a mesenchymal phenotype in 
LPA-treated MCAs, characterized by loss of E-cadherin, gain of vimentin expression, rearrangement of F-actin 
stress fibers and punctate vinculin  staining48. Clustering of β1 integrins was also observed, accompanied by an 
increase in the population of conformationally active β1 integrins, potentially activating signaling pathways that 
promote a more mesenchymal  phenotype7, 48.
Cytoreductive surgery in patients with miliary intraperitoneal dissemination of advanced high grade serous 
ovarian carcinoma (HGSOC) is associated with a greater level of surgical complexity together with a higher 
residual disease  score49. Furthermore, compromised MCAs with repressed peritoneal adhesion function may 
harness alternative metastasis patterns. In support of that, a recent  study27 demonstrated that interference with 
ovarian cancer spheroid formation and inhibition of spheroid-to-mesothelial adhesion through targeting CD44 
blocked mesenteric colonization but instead provoked unrestrained distant in vivo metastases in the thoracic 
cavity and liver.
An unanticipated finding of the current work is that LPA most effectively affects survival, mesothelial clear-
ance and peritoneal implantation of epithelial-type OvCa429  MCAs24. A recent  study50 outlined the necessity of 
Figure 4.  LPA regulates MCA peritoneal adhesion and mesothelial clearance activities. MCAs were generated 
from fluorescently labeled OvCa429, DOV13, and SKOV3ip cells via the hanging drop method with or without 
80 µM LPA (3D+ or 3D−, respectively), seeded atop C57Bl/6 murine peritoneal explants and incubated, as 
indicated in “Methods”; tissues were then examined using EVOS fluorescence microscope or SEM FEI-Magellan 
400, as stated in “Methods”; (A,C,E) quantitative analysis of fluorescent images was performed in ImageJ and 
statistical significance (defined as *p < 0.05; N.S. non-significant) was calculated using a two-sided Mann–
Whitney U test. The data are presented as mean ± SEM (n > 35); (B, D, F) representative scanning electron 
micrographs of MCAs attached to peritoneal explants were taken at × 2,500 and × 10,000 magnifications 
(scale bars as indicated). Col (red) compromised/naked collagen, Mes (white) intact mesothelium, Mes (red) 
compromised/cleared mesothelium, OvCa (white) competent ovarian cancer MCA, OvCa (red) compromised/
dead ovarian cancer MCA, white arrows indicate places of active mesothelial clearance by EOC MCA leading 
cells.
Figure 5.  LPA modulates host peritoneal tissue ultrastructure. (A) C57Bl/6 mice were intraperitoneally 
administered 1 × PBS (1 ml), 80 μM LPA (1 ml) or left non-injected for 5 consecutive days; murine peritoneal 
tissues were then dissected, processed for SEM as detailed in “Methods”; and examined using FEI-Magellan 400 
field emission SEM. Representative images were taken at × 10,000, and × 50,000 magnifications (scale bars as 
indicated). Quantitative analysis of mesothelial cell surface microvilli (B) density, (C) length, and (D) thickness 
was assessed using standard Fiji open source software. The data are presented as mean ± SD, n = 250. Statistical 
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E-cadherin as a survival factor for detached cancer cells and a requirement for successful distant metastatic re-
colonization in multiple mouse and human models of breast carcinomas. Conversely, loss of E-cadherin triggered 
reactive oxygen-induced circulating tumor cell apoptosis and restricted early phases of metastatic  seeding50. Our 
observation that LPA-treated OvCa429 MCAs exhibit dissociation and cell death on intact mesothelial tissues 
is consistent with these data and suggest a link to an LPA-induced loss of E-cadherin from OvCa429 cell/MCA 
 surface43. Importantly, E-cadherin-negative  DOV1324 and  SKOV3ip7 MCAs displayed incomplete segregation and 
apoptosis while retaining partial capacity to further penetrate mesothelium, suggesting that mesenchymal-type 
E-cadherin-deficient cells/MCAs possess alternative survival mechanisms. In agreement with that is our mass 
spectrometry  analysis44 that reports divergent lists of peptides released from OvCa429 and SKOV3ip MCAs by 
LPA, suggesting differential responses of epithelial- and mesenchymal-type cells to LPA-induced stress.
In addition to exploring the impact of LPA on EOC cell/MCA structure and function, the current study also 
addressed the response of host peritoneal tissues to this bioactive phospholipid in vivo and ex vivo. Our data 
indicated activation of mesothelial cells, as evidenced through alterations in their surface morphology with 
increased number and elongation of surface microvilli, which functionally resulted in mitigation of EOC cell 
and epithelial-type MCA adhesion. These results support a protective role of the mesothelium as a bioactive 
mechanical barrier against tumor cell peritoneal anchorage and  colonization21, 45, 46. Notably, activated mesothe-
lial cells successfully blocked adhesion of all three types of EOC single cells which is consistent with our previ-
ous observations of single cell-mesothelium  interaction21. Meanwhile, LPA-mediated activation of mesothelial 
cells was efficient in suppressing epithelial-type OvCa429 MCA implantation, but was not sufficient to inhibit 
seeding of mesenchymal-type DOV13 and SKOV3ip MCAs. These results align with research indicating that 
ovarian cancer spheroids harnessing a mesenchymal gene signature possess an augmented capacity for meso-
thelial  clearance21, 51. Together these data support a role for LPA in promoting the differential implantation of 
mesenchymal-type metastatic cell clusters at secondary metastatic sites and indicate that LPA-induced changes 
to both the tumor and the host are important in regulating adhesive events in metastasis. This is supported by 
clinical data showing that HGSOC patients with miliary intraperitoneal disease predominantly present lesions 
of mesenchymal molecular  subtype49 and highlight a need for continued evaluation of anti-metastatic therapies 
targeting mesenchymal-type MCAs.
Figure 6.  LPA alters mesothelial susceptibility to colonizing EOC cells and MCAs. (A) Schematic 
representation of the peritoneal adhesion assay workflow: C57Bl/6 mice were intraperitoneally administered 
80 μM LPA (1 ml) or left non-injected for 5 consecutive days; murine peritoneal tissues were then dissected, 
fluorescently labeled OvCa429, DOV13, or SKOV3ip cells or pre-generated MCAs (via hanging drop method), 
were seeded atop and incubated as detailed in “Methods”; tissues were then examined using EVOS fluorescence 
microscope or SEM FEI-Magellan 400; (B,C) quantitative analysis of images was performed in ImageJ and 
statistical significance (defined as *p < 0.05, **p < 0.01, ****p < 0.0001, N.S. non-significant) was calculated using 
a two-sided Mann–Whitney U test. The data are presented as mean ± SD (B) and mean ± SEM, n > 35 (C).
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Materials and methods
cell lines. DOV13 and OvCa429 are human ovarian cancer cell lines that have been obtained from Dr. 
RC Bast, MD Anderson Cancer Center, Houston TX. Cells were maintained in Minimal Essential Medium 
(MEM; Gibco, Big Cabin, OK) containing 10% Fetal Bovine Serum (FBS; Gibco), 1% Non-Essential Amino 
Acids (Corning Cellgro, Manassas, VA), 1% Penicillin/Streptomycin (Lonza, Allendale, NJ), 1% Sodium Pyru-
vate (Corning Cellgro), 0.1% Amphotericin B (Cellgro), and supplemented with 10 μg/ml Insulin (Gibco) for 
DOV13 cell medium  only21, 24, 26, 43. Human EOC SKOV3ip cells were obtained from Dr. Katherine Hale (Uni-
versity of Texas M.D. Anderson Cancer Center, Houston, TX) and maintained in RPMI-1640 medium (Corning 
Cellgro), supplemented with 10% FBS, 1% l-glutamine (Gibco by Life Technologies), 1% sodium pyruvate, 1% 
Pen/Strep, 1% NEAA, 1% 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (Gibco by Life Technologies), 
and 0.1% Amphotericin  B44. Cell lines were tested and authenticated by Genetica DNA Laboratories using short 
tandem repeat (STR) DNA profiling and were found to be > 95%  concordant21, 24, 26, 43.
RFP lentiviral vector (GenTarget, San Diego, CA) was used to generate fluorescently tagged OvCa429-RFP and 
SKOV3ip-RFP cell lines. GFP lentiviral vector (AddGene, Cambridge, MA) was utilized to create DOV13-GFP 
stable cell line. Lentiviral transductions were performed according to manufacturers’ protocols and successfully 
tagged cells were further selected via BD FACSAria III cell  sorter21.
McA formation. Two-dimensional (2D) EOC cell monolayers were grown in tissue culture (TC) dishes and 
a hanging drop method was employed to form free-floating three-dimensional (3D) ovarian cancer  MCAs52,53. 
LPA was purchased from Avanti Polar Lipids, Inc. (Alabaster, Alabama) and four different LPA treatment regi-
mens were applied during MCA generation (Fig. 1): (1) cells remained untreated in both 2D TC dishes and 
3D hanging drops (designated ‘2D − 3D−’); (2) cells were treated with LPA in hanging drops only (designated 
‘2D − 3D+’); (3) cells were treated with LPA in TC dishes only (designated ‘2D + 3D−’); (4) cells were treated with 
LPA both in TC dishes and in hanging drops (designated ‘2D + 3D+’). Briefly, cells were grown in TC dishes until 
60–70% confluence, incubated with or without 80 µM LPA for 24 h, harvested, centrifuged and re-suspended in 
fresh medium at 100,000 cell/ml (for MCA electron microscopy) or 5,000 cell/ml (for ex vivo peritoneal adhe-
sion assay) with or without 80 µM LPA. Droplets (20 μl) were seeded on the inner surface of a 150 × 25 mm tissue 
culture dish lid. Phosphate-buffered saline (PBS; Corning Cellgro) was added to the lower dish and the lid was 
gently inverted atop the dish. Cells were incubated at 37 °C for 48 h and MCA formation was confirmed by light 
microscopy.
Mouse intraperitoneal injections. C57Bl/6 female mice (n = 6, Jackson Laboratories, Bar Harbor, ME) 
were intraperitoneally injected with 1 ml of 80 µM LPA in PBS, 1 ml of PBS or left non-injected. Injections 
were performed for 5 consecutive days with the injection site (left and right) switched daily. Mice were then 
euthanized by  CO2 inhalation and subsequent cervical dislocation, peritoneal explants were dissected from the 
murine ventral surface and either processed directly for scanning electron microscopy (SEM) or used for an 
ex vivo peritoneal adhesion assay. All animal procedures were approved by the University of Notre Dame Insti-
tutional Animal Care and Use Committee (protocol 17-07-3998) and were carried out in accordance with the 
regulations of the same.
ex vivo cell/MCA peritoneal adhesion assay. Cell/MCA adhesion to murine peritoneum was assessed 
using ex vivo explants of intact peritoneal  tissue54, 55. C57Bl/6 female mice (Jackson Laboratories) were dissected 
using a ventral midline incision; 4 peritoneal tissue pieces were removed and pinned to the bottom of 24-well 
dishes pre-coated with optically transparent silicone using Sylgard 184 Silicone Elastomer Kit (Fisher, Waltham, 
MA). For some experiments, prior to peritoneal tissue extraction, mice were subjected to intraperitoneal injec-
tions of 80 µM LPA for 5 consecutive days as detailed above. To examine adhesion of individual cells to perito-
neal explants, fluorescently labeled EOC cells (200,000 cell/ml), pre-treated or not treated with 80 µM LPA (des-
ignated as 2D+ or 2D−), were applied atop murine peritoneal explants and incubated ex vivo for 30 min, 1 and 
2 h, as indicated. For peritoneal adhesion of MCAs, fluorescently tagged non-treated (2D − 3D−) or LPA-treated 
(2D + 3D+) clusters were produced as detailed above and incubated atop murine peritoneal explants (480 MCAs 
per 1 explant). The assay was stopped after 4 h with 3 × 3 min ice-cold PBS washes and cells/peritoneum were 
imaged with AMG EVOS fluorescence microscope. All assays were performed in quadruplicate with triplicate 
samples subjected to quantitative and statistical analysis as described below. The fourth explant was subjected to 
SEM processing and imaging.
Scanning electron microscopy (SeM). MCAs were generated via the hanging drop method, collected 
and fixed in primary fixative solution (2% Glutaraldehyde, 2% Paraformaldehyde in 0.1 M Cacodylate buffer 
pH 7.35), washed, processed with 1% Osmium tetroxide in 0.1 Cacodylate buffer and dehydrated as published 
 previously24. Primary fixation, washing, secondary processing with 2% Osmium tetroxide and dehydration of 
mouse peritoneal explants was described  in21, 24. Critical point drying was performed using Autosamdri-931 
(Tousimis Research Corporation), samples were placed on carbon stubs, sputter coated with iridium, and exam-
ined under FEI-Magellan 400 field emission SEM. Electron micrograph false colorization was applied using 
Adobe Photoshop CC 2014 software.
Quantitative image and statistical analysis. For analysis of ex vivo cell and MCA peritoneal adhe-
sion, murine tissues were imaged (six fields of view per each explant that was incubated with single cells or the 
total area of MCA-seeded tissue, three biological replicates per each experiment), image analysis was performed 
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with ImageJ (free download). The measured number of attached MCAs for each size group (small, 3–10 cells; 
medium, 11–50 cells; large, > 50 cells) were normalized by the mean number of attached MCAs of the corre-
sponding control (no LPA-treatment). For quantitative analysis of ultrastructural differences between murine 
peritoneal explants, the length and thickness of the mesothelial microvilli were measured using standard Fiji 
open source  software56 measurement tool applied to SEM micrographs, taken in three distinct areas of both 
left and right peritoneum compartments per each mouse (Supplemental Fig. 2). Microvilli surface density was 
quantified as the relative area of microvilli fibers in SEM segmented micrographs assessed using standard Fiji 
measurement tool. For all assays, statistical significance (defined as p < 0.05) was calculated using a two-sided 
Mann–Whitney U test. Adobe Photoshop CC2014 software was used in figure preparation.
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